Drugs / BAY2701439
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04147819 | Jul 2020 → Aug 2023 | carcinoma | Bayer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2701439 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04147819 ↗ |
| Action | Deplete | “The alpha particles are expected to damage the tumor cells and cause them to die” NCT04147819 ↗ |
| Modality | Protein / enzyme biologic | “The thorium-227 in the drug is attached to an 'antibody' (large protein)” NCT04147819 ↗ |
| Route | Intravenous | “Intravenous (IV) injection” NCT04147819 ↗ |